Navigation Links
Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in,Journal of American College of Cardiology

SAN CARLOS, Calif., June 19, 2007 /PRNewswire-FirstCall/ -- Nuvelo, Inc. today announced the publication of the Phase 2 proof-of-concept data from the Anthem (Anticoagulation with rNAPc2 To Help Eliminate MACE)/TIMI 32 clinical trial (N=255) in the June 26th issue of the Journal of of Cardiology (JACC), demonstrating that higher-dose (greater than or equal to 7.5 mcg/kg) recombinant nematode anticoagulant protein c2 (rNAPc2) reduced the incidence and duration of ischemia as measured by 7-day continuous electrocardiogram (ECG) by more than 50% and did not statistically significantly increase bleeding in patients being treated with standard antithrombotics and an early invasive approach for non-ST-elevation acute coronary syndromes (NSTE-ACS).

"In clinical studies of other antithrombotics, suppression of ischemia monitored by continuous ECG has been associated with a reduction in clinical ischemic events," said Dr. Robert Giugliano, M.D., S.M., Investigator, TIMI Study Group, Associate Physician, Brigham and Women's Hospital and Assistant Professor of Medicine, Harvard Medical School. "In the ANTHEM/TIMI 32 trial, the ability of higher-dose rNAPc2 to reduce ischemia in patients that are already receiving antithrombotic therapy is very exciting, and we look forward to future studies to further understand rNAPc2's potential in this patient population."

ANTHEM/TIMI 32 Study Details and Results

The ANTHEM/TIMI 32 trial consisted of two stages, a dose escalation safety stage and a heparin replacement stage. All patients in the study had 3-lead Holter monitors for assessment of cardiac ischemia, measurement of prothrombin time and F1+2 concentration, and clinical follow-up for up to six months.

The first stage was a double-blind, placebo-controlled, dose escalation study which investigated the safety of rNAPc2 in combination with other antithrombotics in 203 patients with NSTE-ACS. These dat
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
3. Nuvelo Announces Publication of NU206 Study Results in Gastroenterology
4. Nuvelo Announces Presentation on NU206 at 2007 American Association for Cancer Research Annual Meeting
5. Nuvelo Announces Presentation on rNAPc2 at American College of Cardiology 56th Annual Scientific Session
6. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
7. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/19/2014)... 2014 In today,s rapidly changing, highly ... tools are essential for survival. The world is ... desires, preferences, and unmet needs are evolving rapidly. ... across all industries are continually searching for innovative ... adoption of new market research techniques like mobile ...
(Date:12/19/2014)... CARDIFF-BY-THE-SEA, Calif. , Dec. 19, ... SRNE ;  Sorrento), an oncology company developing new ... Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ... based therapy, announced today that the companies have ... next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies for ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Somewhere ... addressing hearing health was forgotten. But Audicus , ... to hear better this new year. Hearing ... facing the aging population, though it is often unaddressed. ... in four has a hearing aid, mainly due to ...
Breaking Medicine Technology:Study Uncovers New Tools and Techniques for Understanding Consumer Decision Making 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5Audicus Will Help People Resolve to Hear Better in 2015 2
... , Feb. 16 Aton Pharma, Inc., ... Wayne S. Mulcahy , Ph.D., has joined the company ... of Princeton Pharma Holdings LLC, Aton is focused on ... and orphan diseases. , The company,s comprehensive portfolio ...
... , KINGWOOD, Texas , Feb. 16 ... www.imaiinc.com announced today that the company has ... interest in Assured Pharmacy, Inc. (Pink Sheets: APHY.PK) ... on selling prescription medications in the chronic pain management ...
Cached Medicine Technology:Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 2International Merchant Advisors, Inc. Signs LOI to Invest in Pharmaceutical Chain 3
(Date:12/22/2014)... 2014 Explorys, the leader in big ... leadership team: Greg Yarrington as Vice President of Operations, ... Wells as Vice President of Solutions. These new leaders ... jobs in 2015 to support client demand for the ... offerings, and growth of its partner network. , ...
(Date:12/22/2014)... 2014 Pasadena sleep apnea ... sleep apnea. Drowsy drivers are 15 times more likely ... well-rested, and some experts believe that sleep-deprived drivers may ... drivers. Unfortunately, millions of Americans may be sleep-deprived without ... Sleep Medicine, about 18 million Americans have sleep apnea, ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... Nursing Leadership Conference, next month in San ... strategies to address dynamics that often stand in ... authority, and competition. , This premier faculty ... Center for Transformational Leadership, whose mission is to ...
(Date:12/21/2014)... 2014 BellasDress.com offers a wide range ... Today, it announces its BellasDress Christmas Sale , ... online store. , BellasDress is a famous online supplier ... fans through a series of promotions. The dress experts ... , “We are proud of offering high quality ...
Breaking Medicine News(10 mins):Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3Health News:BellasDress.com Announces its BellasDress Christmas Sale 2
... LYMAN, S.C., Sept. 11 Southern Home Medical,Equipment, Inc. ... the month of August 2008 compared to July 2008., ... stated, "On the heels of,reporting record sales in the ... on a path of strong sales momentum. Encore Medical ...
... against women in a family also has serious consequences ... sling Monemi from Uppsala University has studied women and ... other things, that children whose mothers are exposed to ... other children. , Kajsa sling Monemi, paediatrician, the ...
... - For Non-US Healthcare Media, - Global ... Improved Survival Outcomes With Vetmedin(R) (pimobendan), Veterinarians and ... promise of an extended happy life together for millions ... that dogs,suffering from the most common type of heart ...
... Residents to Eat Right, Move More ... and Milk Their Diets, BOSTON, Sept. 11 ... fad diets -- which seem to go in and out of,fashion like shoulder ... -- including 51 percent of Massachusetts,residents -- remain overweight or obese., A ...
... 11 Oculus Innovative,Sciences, Inc. (Nasdaq: OCLS ), ... of products based upon the Microcyn(R),Technology platform, today announced ... exclusive interview on WallSt.net,s 3-Minute Press Show., The ... the,significance of the company,s latest press release., ...
... Plastic surgeon offers the surprise scoop, NEW ... time and an,active lifestyle can impact a person,s ... million Americans turned to cosmetic procedures last,year to ... Shirley Madhere, M.D., says you can improve your ...
Cached Medicine News:Health News:Southern Home Medical Announces Revenues Up 172% for the Month of August 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 2Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 3Health News:Landmark Research Heralds New Era in Dog Heart Treatment and Longer Life for Dogs 4Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Boston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:[video] Hojabr Alimi, CEO of Oculus Innovative Sciences, Inc. Discusses Reduction of Planned Expenses on WallSt.net's 3-Minute Press Show 2Health News:Insider Secrets for Beautiful Skin 2
... RELISA ENA Multiparameter Kit is ... for six of the most ... a unique quality control system. ... Check) well in each strip ...
... RELISA ENA assays were designed with the ... clinician in the diagnosis of autoimmune disease. ... disease and 1,000 normal individuals were tested ... Test System. Immuno Concepts compared the results ...
... functional human C1q coated in the solid phase ... stage, CIC in the diluted patient samples and ... into the C1q coated assay wells. After incubation, ... and a ready to use conjugate (goat anti-human ...
... CIC are formed as a host ... cleared by phagocytosis. If not cleared, CIC ... inflammatory response. CIC are increased in Systemic ... may be involved in other autoimmune disorders ...
Medicine Products: